Similar to our results, He et al. found four metabolism-associated genes (GAS2, SLC17A4, NTM, and GC) is potential for predicting prognosis, and chemo-/immuno-therapy response in prostate cancer patients [61]. This evidence concerns the gene SLC17A4 and prostate cancer.